AADvac1 vs ACI-35.030
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Tau · full Alzheimer's Disease pipeline
AADvac1
Developed by Axon Neuroscience
NCT02579252 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 208 participants, with safety as its primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Safety (all-case treatment-emergent adverse events except local reactions)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: August 2028 · NCT06957418 (registry estimate)
Reported efficacy
Safety (all-case treatment-emergent adverse events except local reactions) (24 months): Primary safety endpoint at 24 months: adverse events in 84.6% of AADvac1-treated (n=117) vs 81.0% of placebo-treated (n=79) participants; serious adverse events in 17.1% (AADvac1) vs 24.1% (placebo). (met)
Result source: NCT02579252
ACI-35.030
Developed by Johnson & Johnson under a licence from AC Immune
NCT04445831 · Phase 1/2 · completed
This was a randomized, quadruple-blinded, placebo-controlled study, which is a strong design foundation, but the enrollment was very small (57 participants split across seven arms, several with only 4-6 subjects), and the primary endpoints were safety/tolerability counts and antibody-titer levels rather than a hard clinical or cognitive outcome - cognitive and functional scales (CDR-SB, RBANS, NPI) were only exploratory and their results were not even posted. Because the primary comparisons here are immunogenicity/safety readouts rather than a statistically tested clinical efficacy endpoint, this evidence is real but limited.
Next expected readout: December 2026 · NCT06544616 (registry estimate)
Reported efficacy
Overview of Treatment-Emergent Adverse Events, Safety Set (AEs falling between first dosing (week 0) and last study visit (week 74), ie up to 74 weeks, defined as Treatment-Emergent Adverse Events (TEAEs)); Overview of Treatment-Emergent Adverse Events Assessed by Intensity, Safety Set (Between the first dosing and the last study visit (week 74)); Overview of Treatment-Emergent Adverse Events Assessed by Relationship to Study Drug, Safety Set (Between the first dosing and the last study visit (week 74)); Mean Change From Baseline in Diastolic Blood Pressure, ITT Set (Endpoint is assessed from baseline (i.e. last non-missing value prior to the first immunization at week 0) to the last study visit (week 74), at weeks 26, 50 and 74.); Mean Change From Baseline in Systolic Blood Pressure, ITT Set (Endpoint is assessed from baseline (i.e. last non-missing value prior to the first immunization at week 0) to the last study visit (week 74), at weeks 26, 50 and 74.); Mean Change From Baseline in Heart Rate, ITT Set (Endpoint is assessed from baseline (i.e. last non-missing value prior to the first immunization at week 0) to the last study visit (week 74), at weeks 26, 50 and 74.); Mean Change From Baseline in Body Temperature, ITT Set (Endpoint is assessed from baseline (i.e. last non-missing value prior to the first immunization at week 0) to the last study visit (week 74), at weeks 26, 50 and 74.); Number of Participants Reporting Suicidal Ideation or Behavior Using Columbia-Suicide Severity Rating Scale (C-SSRS), ITT Set (Endpoint is assessed from baseline (i.e. last non-missing value prior to the first immunization at Visit 1 (Week 0) or Screening) to the last study visit (week 74), at weeks 26, 50 and 74.); Number of Participants With Abnormal MRI Results, ITT Set (Endpoint is assessed from baseline (screening) to the last study visit (week 74), at weeks 10, 26, 50 and 74.); Anti-pTau IgG Antibody Response in Serum - Antibody Titers, ITT Set (Endpoint is assessed from baseline (i.e. mean of the titers measured at the screening and visit 1 before the first study drug administration) to the last study visit (week 74), at weeks 0, 2, 8, 10, 24, 26, 36, 48, 50, 67 and 74.); Anti-ePHF IgG Antibody Response in Serum - Antibody Titers, ITT Set (Endpoint is assessed from baseline (i.e. mean of the titers measured at the screening and visit 1 before the first study drug administration) to the last study visit (week 74), at weeks 0, 2, 8, 10, 24, 26, 36, 48, 50, 67 and 74.): Overview of Treatment-Emergent Adverse Events, Safety Set (AEs falling between first dosing (week 0) and last study visit (week 74), ie up to 74 weeks, defined as Treatment-Emergent Adverse Events (TEAEs)): Sub-Cohort 1.1 (ACI-35.030 300 μg) — Any TEAE: 6 Participants; Any Serious TEAE: 2 Participants; Any Severe TEAE: 1 Participants; Any Adverse Drug Reactions: 3 Participants; Any Serious Adverse Drug Reactions: 0 Participants; Any TEAE Leading to Study Drug Discontinuation: 0 Participants; Any TEAE Leading to Study Discontinuation: 0 Participants; Any TEAE with Outcome of Death: 0 Participants | Sub-Cohort 1.2 (ACI-35.030 900 μg) — Any TEAE: 17 Participants; Any Serious TEAE: 2 Participants; Any Severe TEAE: 2 Participants; Any Adverse Drug Reactions: 15 Participants; Any Serious Adverse Drug Reactions: 1 Participants; Any TEAE Leading to Study Drug Discontinuation: 0 Participants; Any TEAE Leading to Study Discontinuation: 0 Participants; Any TEAE with Outcome of Death: 0 Participants | Sub-Cohort 1.3 (ACI-35.030 1800 μg) — Any TEAE: 6 Participants; Any Serious TEAE: 2 Participants; Any Severe TEAE: 0 Participants; Any Adverse Drug Reactions: 6 Participants; Any Serious Adverse Drug Reactions: 0 Participants; Any TEAE Leading to Study Drug Discontinuation: 0 Participants; Any TEAE Leading to Study Discontinuation: 0 Participants; Any TEAE with Outcome of Death: 0 Participants | Cohort 1 Placebo — Any TEAE: 8 Participants; Any Serious TEAE: 0 Participants; Any Severe TEAE: 0 Participants; Any Adverse Drug Reactions: 2 Participants; Any Serious Adverse Drug Reactions: 0 Participants; Any TEAE Leading to Study Drug Discontinuation: 0 Participants; Any TEAE Leading to Study Discontinuation: 0 Participants; Any TEAE with Outcome of Death: 0 Participants | Sub-Cohort 2.1 (JACI-35.054 15 μg) — Any TEAE: 6 Participants; Any Serious TEAE: 0 Participants; Any Severe TEAE: 0 Participants; Any Adverse Drug Reactions: 4 Participants; Any Serious Adverse Drug Reactions: 0 Participants; Any TEAE Leading to Study Drug Discontinuation: 0 Participants; Any TEAE Leading to Study Discontinuation: 0 Participants; Any TEAE with Outcome of Death: 0 Participants | Sub-Cohort 2.2 (JACI-35.054 60 μg) — Any TEAE: 6 Participants; Any Serious TEAE: 0 Participants; Any Severe TEAE: 0 Participants; Any Adverse Drug Reactions: 2 Participants; Any Serious Adverse Drug Reactions: 0 Participants; Any TEAE Leading to Study Drug Discontinuation: 0 Participants; Any TEAE Leading to Study Discontinuation: 0 Participants; Any TEAE with Outcome of Death: 0 Participants | Cohort 2 Placebo — Any TEAE: 4 Participants; Any Serious TEAE: 1 Participants; Any Severe TEAE: 1 Participants; Any Adverse Drug Reactions: 0 Participants; Any Serious Adverse Drug Reactions: 0 Participants; Any TEAE Leading to Study Drug Discontinuation: 0 Participants; Any TEAE Leading to Study Discontinuation: 0 Participants; Any TEAE with Outcome of Death: 0 Participants (not_applicable)
Result source: NCT04445831
Results for Alzheimer's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | AADvac1 | ACI-35.030 |
|---|---|---|
| CDR-SB, change | —Not reported | —Not reported |
| ADAS-Cog11, change | —Not reported | —Not reported |
| ADCS-ADL, change | —Not reported | —Not reported |
| MMSE, change | —Not reported | —Not reported |
| Amyloid PET, change (centiloids) | —Not reported | —Not reported |
CDR-SB, change
- AADvac1
- —Not reported
- ACI-35.030
- —Not reported
ADAS-Cog11, change
- AADvac1
- —Not reported
- ACI-35.030
- —Not reported
ADCS-ADL, change
- AADvac1
- —Not reported
- ACI-35.030
- —Not reported
MMSE, change
- AADvac1
- —Not reported
- ACI-35.030
- —Not reported
Amyloid PET, change (centiloids)
- AADvac1
- —Not reported
- ACI-35.030
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
AADvac1: no structured comparison results are available for Alzheimer's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. AADvac1: 0 of 4 rows · ACI-35.030: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | ACI-35.030 |
|---|---|
| Dropout rate | 16.7%1800 μga NCT04445831 · Phase 1/2 |
| Discontinued due to AEs | —1800 μga NCT04445831 · Phase 1/2 |
| Serious AEs | 33.3%1800 μga NCT04445831 · Phase 1/2 |
| Most frequent reported AEs | 1800 μga injection site reaction 100% (placebo 0%) headache 50% (placebo 0%) covid-19 33.3% (placebo 30%) NCT04445831 · Phase 1/2 show 2 more results900 μg injection site reaction 73.7% (placebo 0%) covid-19 36.8% (placebo 30%) fatigue 21.1% (placebo 20%) NCT04445831 · Phase 1/2 300 μg nasopharyngitis 50% (placebo 10%) injection site reaction 33.3% (placebo 0%) abdominal pain 16.7% (placebo 0%) NCT04445831 · Phase 1/2 |
Notes
- aPopulation comparability has not been reviewed for these studies.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AADvac1's landscape · ACI-35.030's landscape